Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-787 in R/R AML
NCT06068868Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Peptide-Drug Conjugates
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of ABBV-787 in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events (AE) up to 3 Years and Maximum Tolerated Dose (MTD) Based on Dose-Limiting Toxicities (DLT) up to 28 Days. Started Nov 2023; status: terminated.
02
Drugs
ABBV-787
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06068868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068868.